Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pipex to meet with FDA following non acceptance of Coprexa NDA

Feb. 5, 2008

European Commission approves Novartis' Galvus as oral treatment for type 2 diabetes

Feb. 5, 2008

Bone Medical reports positive data from second clinical trial of CaPTHymone for osteoporosis

Feb. 5, 2008

AMAG provides additional information on clinical development program for ferumoxytol

Feb. 4, 2008

QUATRx reports results from two phase I clinical studies of sobetirome

Feb. 4, 2008

Ipsen withdraws application to EMEA for extension of indication for Nutropin AQ

Feb. 1, 2008

FDA issues complete response letter for Lev Pharmaceuticals' Cinryze

Jan. 31, 2008

Radius launches RAD-1901 clinical program for the treatment of hot flashes

Jan. 31, 2008

Lipoxen initiates phase I trial of SuliXen for type 1 and type 2 diabetes

Jan. 31, 2008

Velcura to initiate clinical trials following successful IND application to FDA

Jan. 31, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...